Leerink Partners Reiterates Outperform Rating on Tenax Therapeutics (TENX) following Q4 results, trial update
Tweet Send to a Friend
Leerink Partners analyst David Risinger reiterated an Outperform rating and $26.00 price target on Tenax Therapeutics (NASDAQ: TENX)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
